LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50

Benzinga Newsdesk www.benzinga.com Positive 65.0%

Neg 0% Neu 0% Pos 65%

LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.